Top

Published in:

01-06-2017 | Review Article

Prognostic impact of PD-1 and its ligands in renal cell carcinoma

Authors: Franziska Erlmeier, Wilko Weichert, Andres Jan Schrader, Michael Autenrieth, Arndt Hartmann, Sandra Steffens, Philipp Ivanyi

Published in: Medical Oncology | Issue 6/2017

Abstract

Programmed death-1 receptor (PD-1) and programmed death-1 receptor-ligand (PD-L1) have been suggested to play a role as prognostic markers in clear cell renal cell carcinoma (ccRCC). The association between PD-L1 and prognosis seems to be more robust than for PD-1. Further, preliminary analyses suggest that neither PD-1 nor its ligands play a role as prognostic markers in non-clear cell RCC, while the prognostic role of PD-L2 in ccRCC as well as in non-clear cell RCC remains unclear.

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803–13. doi:10.1056/NEJMoa1510665.CrossRefPubMed

Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, et al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J Clin Oncol. 2015;33(13):1430–7. doi:10.1200/JCO.2014.59.0703.CrossRefPubMed

McDermott DF, Sosman JA, Sznol M, Massard C, Gordon MS, Hamid O, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a Phase Ia study. J Clin Oncol. 2016;34(8):833–42. doi:10.1200/JCO.2015.63.7421.CrossRefPubMed

Larkin JMG, Gordon MS, Thistlethwaite F, Nathan PD, Rini BI, Martignoni M, Shnaidman M, Chiruzzi C, Di Pietro A, Choueiri TK, The Royal Marsden NHS Foundation Trust, London, United Kingdom. Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma. 2016 ASCO Annual Meeting; 2016.

Choueiri TK, Hodi FS, Thompson JA, McDermott DF, Hwu W-J, Lawrence DP, Dawson NA, Wong DJL, Bhatia S, James M, Shu X, Moreno BH, Ibrahim N, Perini RF, Ribas A, Atkin MB. Pembrolizumab (pembro) plus low-dose ipilimumab (ipi) for patients (pts) with advanced renal cell carcinoma (RCC): phase 1 KEYNOTE-029 study. 2017 Genitourinary Cancers Symposium; 2017.

Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887–95.PubMedPubMedCentral

Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, et al. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 2011;71(16):5393–9. doi:10.1158/0008-5472.CAN-11-0993.CrossRefPubMed

Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. doi:10.1016/j.eururo.2016.02.029.CrossRefPubMed

Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27(5):612–24.CrossRefPubMed

10.

Steffens S, Janssen M, Roos FC, Becker F, Steinestel J, Abbas M, et al. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma. Hum Pathol. 2014;45(12):2411–6. doi:10.1016/j.humpath.2014.08.002.CrossRefPubMed

11.

Abbas M, Steffens S, Bellut M, Becker JU, Grosshennig A, Eggers H, et al. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma? Med Oncol. 2016;33(6):59. doi:10.1007/s12032-016-0770-8.CrossRefPubMed

12.

Erlmeier F, Hartmann A, Autenrieth M, Wiedemann M, Ivanyi P, Steffens S, et al. PD-1/PD-L1 expression in chromophobe renal cell carcinoma: an immunological exception? Med Oncol. 2016;33(11):120. doi:10.1007/s12032-016-0833-x.CrossRefPubMed

13.

Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, et al. Tim-3 expression on tumor-infiltrating PD-1 + CD8 + T cells correlates with poor clinical outcome in renal cell carcinoma. Cancer Res. 2017;77(5):1075–82. doi:10.1158/0008-5472.CAN-16-0274.CrossRefPubMed

14.

MacFarlane AW, Jillab M, Plimack ER, Hudes GR, Uzzo RG, Litwin S, et al. PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. Cancer Immunol Res. 2014;2(4):320–31. doi:10.1158/2326-6066.CIR-13-0133.CrossRefPubMed

15.

Skar RS. PD-1 expression and its impact on survival in localized clear cell renal cell carcinoma. J Clin Oncol. 2016;34(suppl 2):568. doi:10.1200/jco.2016.34.2_suppl.568.

16.

Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757–61. doi:10.1158/1078-0432.CCR-06-2599.CrossRefPubMed

17.

Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 2006;66(7):3381–5. doi:10.1158/0008-5472.CAN-05-4303.CrossRefPubMed

18.

Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, et al. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1749–56. doi:10.1158/1078-0432.CCR-06-2129.CrossRefPubMed

19.

Shin SJ, Jeon YK, Kim PJ, Cho YM, Koh J, Chung DH, et al. Clinicopathologic analysis of PD-L1 and PD-L2 expression in renal cell carcinoma: association with oncogenic proteins status. Ann Surg Oncol. 2016;23(2):694–702. doi:10.1245/s10434-015-4903-7.CrossRefPubMed

20.

Leite KR, Reis ST, Junior JP, Zerati M, Gomes Dde O, Camara-Lopes LH, et al. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis. Diagn Pathol. 2015;10:189. doi:10.1186/s13000-015-0414-x.CrossRefPubMedPubMedCentral

21.

Scheel AH, Dietel M, Heukamp LC, Johrens K, Kirchner T, Reu S, et al. Predictive PD-L1 immunohistochemistry for non-small cell lung cancer: current state of the art and experiences of the first German harmonization study. Pathologe. 2016;37(6):557–67. doi:10.1007/s00292-016-0189-1.CrossRefPubMed

22.

Xu F, Xu L, Wang Q, An G, Feng G, Liu F. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. Int J Clin Exp Med. 2015;8(9):14595–603.PubMedPubMedCentral

23.

Iacovelli R, Nole F, Verri E, Renne G, Paglino C, Santoni M, et al. Prognostic role of PD-L1 expression in renal cell carcinoma. A systematic review and meta-analysis. Target Oncol. 2016;11(2):143–8. doi:10.1007/s11523-015-0392-7.CrossRefPubMed

24.

Abbas M, Steffens S, Bellut M, Eggers H, Grosshennig A, Becker JU, et al. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC). Med Oncol. 2016;33(7):80. doi:10.1007/s12032-016-0794-0.CrossRefPubMed

25.

Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–84. doi:10.1093/annonc/mdu445.CrossRefPubMedPubMedCentral

26.

Motoshima T, Komohara Y, Ma C, Dewi AK, Noguchi H, Yamada S, et al. PD-L1 expression in papillary renal cell carcinoma. BMC Urol. 2017;17(1):8. doi:10.1186/s12894-016-0195-x.CrossRefPubMedPubMedCentral

27.

Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48(3):207–17.CrossRefPubMed

28.

Vera-Badillo FE, Conde E, Duran I. Chromophobe renal cell carcinoma: a review of an uncommon entity. Int J Urol. 2012;19(10):894–900. doi:10.1111/j.1442-2042.2012.03079.x.CrossRefPubMed

29.

Erlmeier F, Weichert W, Autenrieth M, Wiedemann M, Schrader AJ, Hartmann A, et al. PD-L2: a prognostic marker in chromophobe renal cell carcinoma? Med Oncol. 2017;34(5):71. doi:10.1007/s12032-017-0926-1.CrossRefPubMed

Title: Prognostic impact of PD-1 and its ligands in renal cell carcinoma
Authors: Franziska Erlmeier
Wilko Weichert
Andres Jan Schrader
Michael Autenrieth
Arndt Hartmann
Sandra Steffens
Philipp Ivanyi
Publication date: 01-06-2017
Publisher: Springer US
Published in: Medical Oncology / Issue 6/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-0961-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

A brief review of the management of platinum-resistant–platinum-refractory ovarian cancer

Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging

Need for new review of article on ketogenic dietary regimes for cancer patients

Post-chemotherapy PD-L1 expression correlates with clinical outcomes in Japanese bladder cancer patients treated with total cystectomy

Prognostic significance of histologic subtype in pStage I lung adenocarcinoma

Antiangiogenics and immunotherapies in cervical cancer: an update and future’s view

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage